Melvin H. Hayes III - 09 Aug 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Chief Operating Officer
Signature
/s/ Gregory Tourangeau, as attorney-in-fact for Melvin Hayes
Issuer symbol
FULC
Transactions as of
09 Aug 2022
Net transactions value
$0
Form type
4
Filing time
11 Aug 2022, 16:15:39 UTC
Next filing
13 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock Option (right to buy) Award $0 +137,000 $0.000000 137,000 09 Aug 2022 Common Stock 137,000 $7.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on August 9, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of August 9, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.